# PHASE 1 – Strategic Architecture & Foundational Development  
## NeuroFusion-AD Initiative  
### Roche Information Solutions Acquisition-Grade Build

---

# 1. Executive Purpose of Phase 1

Phase 1 establishes the strategic, technical, regulatory, and data foundation required to build **NeuroFusion-AD** as a Roche-acquisition-ready digital asset.

This phase focuses on:

- Translating Roche’s Navify ecosystem into technical requirements
- Architecting a Navify-ready multimodal AI system
- Designing regulatory-grade software infrastructure
- Establishing dataset acquisition strategy
- Building a reproducible AI training and inference pipeline
- Aligning product architecture with Roche’s “Reagent Pull-Through” strategy

---

# 2. Strategic Context

## Industry Shift

**Old Model:** Analyzer + Reagents  
**New Model:** Data + Algorithms + Clinical Insight  

Roche Information Solutions (RIS) consolidated digital health under the Navify brand to create a unified clinical decision infrastructure.

NeuroFusion-AD must:

- Integrate seamlessly into Navify
- Drive Elecsys pTau-217 assay utilization
- Function as Clinical Decision Support (CDS), not a standalone diagnostic

---

# 3. Roche Navify Ecosystem Alignment

## Navify Architecture Pillars

### 1. Digital Infrastructure
Bridges:
- cobas analyzers
- Laboratory Information Systems (LIS)
- Electronic Medical Records (EMR)

Standards required:
- HL7 v2.x
- FHIR APIs
- REST HTTPS/JSON

### 2. Operational Excellence
Not primary target of this initiative.

### 3. Medical Insights (Target Pillar)
Includes:
- Navify Tumor Board
- Navify Digital Pathology
- Navify Algorithm Suite

NeuroFusion-AD must be deployable inside the **Navify Algorithm Suite**.

---

# 4. Product Definition

## Indication for Use

Clinical Decision Support tool predicting:

- Probability of amyloid positivity
- Risk of progression from Mild Cognitive Impairment (MCI) to Alzheimer’s dementia within 24 months

## Target Users

- Primary Care Physicians (triage)
- Neurologists (prognostic staging)

## Outputs

1. Risk Stratification Score (High / Medium / Low)
2. 24-month cognitive decline trajectory
3. Next Best Action recommendation (e.g., Order Elecsys pTau-217)

---

# 5. System Architecture Overview

NeuroFusion-AD will consist of:

- Data ingestion layer
- Feature engineering pipeline
- Graph construction engine
- Cross-modal attention fusion layer
- Risk scoring module
- Explainability engine
- FHIR response generator
- Audit logging system

---

# 6. AI Architecture

## 6.1 Graph Neural Network (GNN)

Medical data is relational and non-Euclidean. A Graph Neural Network enables:

- Patient Similarity Network (PSN)
- Node-based feature learning
- Longitudinal progression modeling

### Graph Structure

- Nodes: Patients
- Edges: Phenotypic similarity
- Node features: Biomarkers + Digital signals + Demographics
- Aggregation: Attention-based graph convolution

---

## 6.2 Cross-Modal Attention Layer

Implements transformer-style attention to:

- Dynamically weight fluid biomarkers vs digital biomarkers
- Provide explainable output

Explainability output example:
- 60% driven by elevated pTau-217
- 40% driven by speech semantic density

---

# 7. Data Modalities

## 7.1 Fluid Biomarkers (Revenue Anchor)

- Plasma pTau-217
- Abeta42/40 ratio
- Neurofilament Light (NfL)

Source:
Roche cobas analyzer → LIS → Navify interface

---

## 7.2 Digital Biomarkers

Collected via smartphone application:

### Acoustic Features
- Jitter
- Shimmer
- Pause duration
- Semantic density

### Motor Features
- Gait speed
- Turn variability
- Accelerometer variance

---

## 7.3 Clinical & Demographic

- Age
- Sex
- Years of education
- APOE ε4 genotype
- MMSE score

Extracted via FHIR resources.

---

# 8. Dataset Strategy

## 8.1 ADNI (Foundational Training)

Purpose:
- Pretraining longitudinal disease progression modeling
- Establishing baseline graph structure

## 8.2 Bio-Hermes (Strategic Validation)

Purpose:
- Align digital biomarkers with Roche blood biomarkers
- Validate cross-modal attention
- Ensure Roche-specific assay compatibility

Action Item:
- Secure Bio-Hermes dataset access
- Map Roche assay outputs to model input schema

---

# 9. Software Engineering Plan

## 9.1 Containerization

- Docker-based deployment
- Non-root execution
- Hardened OS base image
- CPU inference capable
- Optional GPU support

---

## 9.2 API Design

### Input (FHIR Resources)

- Patient
- Observation
- DiagnosticReport
- QuestionnaireResponse

### Output

FHIR `RiskAssessment` resource including:

- Probability score
- Confidence interval
- Explainability metadata
- Recommendation field

---

## 9.3 Deployment Modes

1. Navify Cloud (AWS-backed)
2. Navify Integrator (Edge deployment)

Both must be supported.

---

# 10. Security & Compliance

Must align with:

- ISO/IEC 27001
- GDPR
- HIPAA
- IEC 62304 (Medical software lifecycle)
- ISO 14971 (Risk management)

---

## Phase 1 Documentation Requirements

- Software Requirements Specification (SRS)
- Design History File (DHF)
- Risk Management File
- Traceability Matrix
- Cybersecurity Threat Model
- Data Governance Policy
- Audit Log Schema

---

# 11. Regulatory Preparation

## United States

Pathway:
- FDA 510(k) De Novo

Claim:
“Aid to diagnosis”

## European Union

Classification:
- MDR Class IIa

---

# 12. Competitive Differentiation

NeuroFusion-AD is:

- Not a manual calculator
- Not imaging-only AI
- Not workflow-only software
- Multimodal (Digital + Fluid)
- Roche assay anchored
- Regulatory structured
- Explainable GNN-based system

---

# 13. Phase 1 Deliverables

### Technical
- Working GNN prototype
- Validated training pipeline
- Containerized inference API
- FHIR-compliant I/O

### Data
- ADNI integrated
- Bio-Hermes access initiated
- Feature engineering pipeline complete

### Regulatory
- IEC 62304 documentation started
- Risk assessment drafted

### Strategic
- Reagent pull-through validation document
- Navify integration blueprint

---

# 14. Phase 1 Timeline

| Month | Milestone |
|--------|------------|
| Month 1 | Dataset acquisition + architecture design |
| Month 2 | GNN prototype training |
| Month 3 | Cross-modal attention integration |
| Month 4 | Containerization + FHIR API |
| Month 5 | Internal validation + documentation |
| Month 6 | Navify-ready demonstration build |

---

# 15. Success Criteria

Phase 1 is complete when:

- Model shows statistically significant predictive performance
- Explainability layer generates interpretable outputs
- API returns valid FHIR RiskAssessment resource
- Container runs in local and cloud environments
- Regulatory documentation framework initiated

---

# End of PHASE_1.md
